XML 72 R61.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segments of Business - Schedule of Reportable Operating Segment (Details)
$ in Millions
3 Months Ended 9 Months Ended
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Segment revenues          
Total revenues $ 95,294 $ 80,898   $ 268,228 $ 232,596
Segment operating profit (loss)          
Total operating profit (loss) 1,224 642   2,831 2,693
Subtotal 1,453 879   3,576 3,362
Corporate expenses, net (160) (203)   (512) (571)
Interest expense (67) (64)   (220) (172)
Income before income taxes 1,226 612   $ 2,844 2,619
Number of reportable segments | segment       4  
Accounts receivable, credit loss expense (reversal)       $ (144) 780
Proceeds from legal settlements 31        
Pre-tax credits related to LIFO accounting       85 89
Restructuring, impairment, and related charges, net 32 4   276 84
Income (loss) from equity method investments       (43)  
Gains (losses) associated with equity investments $ 6 0   101 0
Rx Savings Solutions, LLC          
Segment operating profit (loss)          
Fair value adjustment gain   2     78
United States          
Segment operating profit (loss)          
Number of reportable segments | segment 3        
Corporate          
Segment operating profit (loss)          
Restructuring, impairment, and related charges, net $ 10 4   34 50
Gains (losses) associated with equity investments       101  
Corporate | Canadian retail disposal group          
Segment operating profit (loss)          
Other comprehensive loss 12     62  
Corporate | National Prescription Opioid Litigation          
Segment operating profit (loss)          
Pre-tax expenses related to estimated litigation liability       51  
U.S. Pharmaceutical          
Segment revenues          
Total revenues 87,110 73,023   244,551 209,949
Segment operating profit (loss)          
Total operating profit (loss) 854 307   2,710 1,727
Accounts receivable, credit loss expense (reversal)   515 $ 210 203 725
Proceeds from legal settlements 31 23   184 220
U.S. Pharmaceutical | Operating Segments          
Segment operating profit (loss)          
Pre-tax credits related to LIFO accounting 89 2   85 89
Restructuring, impairment, and related charges, net 2 (5)   67 6
U.S. Pharmaceutical | Operating Segments | National Prescription Opioid Litigation          
Segment operating profit (loss)          
Pre-tax expenses related to estimated litigation liability       57  
Prescription Technology Solutions          
Segment revenues          
Total revenues 1,371 1,205   3,877 3,589
Segment operating profit (loss)          
Total operating profit (loss) 219 178   627 647
Prescription Technology Solutions | Operating Segments          
Segment operating profit (loss)          
Restructuring, impairment, and related charges, net 0 2   5 7
Medical-Surgical Solutions          
Segment revenues          
Total revenues 2,949 3,031   8,533 8,476
Segment operating profit (loss)          
Total operating profit (loss) 269 268   546 739
Medical-Surgical Solutions | Operating Segments          
Segment operating profit (loss)          
Restructuring, impairment, and related charges, net 19 3   169 9
International          
Segment revenues          
Total revenues 3,860 3,639   11,260 10,582
Segment operating profit (loss)          
Total operating profit (loss) 111 126   (307) 249
International | Canadian retail disposal group | Held-for-sale          
Segment operating profit (loss)          
Canadian businesses held for sale 11     604  
International | Operating Segments          
Segment operating profit (loss)          
Restructuring, impairment, and related charges, net 1 0   1 12
Corporate          
Segment revenues          
Total revenues $ 4 $ 0   $ 7 $ 0
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | U.S. Pharmaceutical          
Segment operating profit (loss)          
Revenue derived from services, percentage (approximately or less than) 1.00%        
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | Prescription Technology Solutions          
Segment operating profit (loss)          
Revenue derived from services, percentage (approximately or less than) 38.00%        
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | Medical-Surgical Solutions          
Segment operating profit (loss)          
Revenue derived from services, percentage (approximately or less than) 1.00%        
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | International          
Segment operating profit (loss)          
Revenue derived from services, percentage (approximately or less than) 1.00%